Why should we measure intact parathyroid hormone (PTH) in a teenager with low 25‑hydroxyvitamin D?

Why Check Parathyroid Hormone (PTH) in a Teenager with Low Vitamin D

Measuring intact PTH when vitamin D is low helps distinguish between appropriate physiological compensation (secondary hyperparathyroidism) and other parathyroid disorders, guides the intensity of vitamin D replacement, and establishes a baseline to monitor treatment response.

The Physiological Rationale

Low vitamin D triggers a compensatory rise in PTH to maintain calcium homeostasis. When 25-hydroxyvitamin D levels fall, the parathyroid glands increase PTH secretion to stimulate conversion of the remaining 25(OH)D to active 1,25-dihydroxyvitamin D, enhance renal calcium reabsorption, reduce phosphate reabsorption, and mobilize calcium from bone 1. This secondary hyperparathyroidism is the body's attempt to prevent hypocalcemia 1, 2.

In chronic kidney disease patients with GFR <60 mL/min/1.73 m², secondary hyperparathyroidism with elevated PTH is common even when plasma 1,25-dihydroxyvitamin D levels appear normal or low-normal, because these "normal" levels are inappropriate in the face of high PTH—indicating defective feedback suppression 3, 1.

Clinical Decision-Making Value

Assessing Severity of Vitamin D Deficiency

PTH elevation correlates with the functional impact of vitamin D deficiency on calcium-phosphate metabolism, not just the absolute 25(OH)D number. A 25-hydroxyvitamin D level below 30 ng/mL represents insufficiency requiring supplementation to prevent progressive secondary hyperparathyroidism, bone demineralization, and increased fracture risk 2. However, the PTH response varies considerably among individuals with identical vitamin D levels 4.

• Only 30% of patients with 25(OH)D <30 ng/mL and 40% of those with 25(OH)D <20 ng/mL actually have elevated PTH 4
• In adolescent females with serum 25(OH)D ≤40 nmol/L (~16 ng/mL), those with higher PTH had significantly lower forearm bone mineral density at both radial and ulnar sites 5
• Levels below 15 ng/mL are associated with greater severity of secondary hyperparathyroidism, even in dialysis patients 2

Excluding Primary Hyperparathyroidism

A teenager with low vitamin D and elevated PTH could have primary hyperparathyroidism (PHP) rather than—or in addition to—secondary hyperparathyroidism from vitamin D deficiency. In primary hyperparathyroidism, low 25(OH)D may result from enhanced conversion to 1,25-dihydroxyvitamin D rather than true deficiency 6. Patients with PHP show:

• Elevated serum calcium (mean 11.4 mg/dL vs 9.6 mg/dL in vitamin D-replete controls) 6
• Elevated 1,25-dihydroxyvitamin D despite low 25(OH)D 6
• PTH that does not normalize with vitamin D supplementation 6
• Exaggerated hypercalcemia when given vitamin D2 supplementation 6

The key distinguishing feature is serum calcium: secondary hyperparathyroidism from vitamin D deficiency maintains normal or low-normal calcium, whereas primary hyperparathyroidism causes hypercalcemia 6.

Guiding Treatment Intensity

Baseline PTH helps determine whether standard or more aggressive vitamin D replacement is needed. For a teenager with 25(OH)D of 14 ng/mL (severe deficiency), the recommended protocol is cholecalciferol 50,000 IU weekly for 8 weeks 2. However:

• If PTH is markedly elevated, closer monitoring is warranted (every 3 months for the first 6 months) 2
• The goal is to achieve 25(OH)D ≥30 ng/mL to suppress PTH and prevent skeletal complications 2
• Some experts target 30-40 ng/mL for optimal health benefits 2

Monitoring Treatment Response

PTH should decline as vitamin D is repleted, but the response is unpredictable. Among patients with elevated PTH at baseline who achieved 25(OH)D ≥30 ng/mL, only 44% reached a normal PTH 4. Of patients with normal PTH at baseline, 59% experienced a drop in PTH while 41% had unchanged or increased PTH despite vitamin D correction 4.

This variability means PTH has limited utility for guiding ongoing vitamin D therapy in individual patients 4, but the baseline measurement remains valuable for:

• Establishing whether secondary hyperparathyroidism exists
• Excluding primary hyperparathyroidism
• Providing a reference point if bone density or calcium metabolism issues arise later

Essential Co-Management

Adequate calcium intake of 1,000-1,500 mg daily from diet and/or supplements is required during vitamin D therapy 2. Vitamin D cannot exert its full bone-protective effect without sufficient dietary calcium for optimal bone response and PTH suppression 2.

Common Pitfalls

• Do not assume all teenagers with low vitamin D will have elevated PTH—only 40% with 25(OH)D <20 ng/mL show PTH elevation 4
• Do not use calcitriol or other active vitamin D sterols to treat nutritional vitamin D deficiency—these are reserved for patients with impaired renal conversion 2, 1
• Do not rely on PTH normalization as the sole endpoint of therapy—target 25(OH)D ≥30 ng/mL regardless of PTH response 2
• Recheck 25(OH)D after 3-6 months of supplementation to confirm adequate response 2, and monitor serum calcium and phosphorus every 3 months after initiating therapy 2
• Measure PTH every 3 months for the first 6 months to assess treatment response 2